Drug intelligence / Profile preview

APL-801

Development stage: Preclinical
Lead developer: Apollomics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APL-801 is a bispecific monoclonal antibody being developed by Apollomics for the treatment of multiple tumor types. It dual-targets the CD40 and PD-L1 pathways, functioning as a CD40 agonist to activate dendritic cells and prime antigen-specific T cells, while simultaneously acting as a PD-L1 antagonist to block immune checkpoint signaling. This combined approach is intended to synergistically enhance the anti-tumor immune response. As of 2024, Apollomics planned to file an Investigational New Drug (IND) application for APL-801, with Phase 1 clinical trial results anticipated in 2025.

Targets

CD40 (Cluster of differentiation 40 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on APL-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-801.

Explore the full profile